Pixie Dust Technologies (NASDAQ:PXDT) & Endonovo Therapeutics (OTCMKTS:ENDV) Critical Contrast

Endonovo Therapeutics (OTCMKTS:ENDV) and Pixie Dust Technologies (NASDAQ:PXDT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.

Profitability

This table compares Endonovo Therapeutics and Pixie Dust Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Endonovo Therapeutics	4,911.97%	-29.58%	755.18%
Pixie Dust Technologies	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Endonovo Therapeutics and Pixie Dust Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Endonovo Therapeutics	0	0	0	0	N/A
Pixie Dust Technologies	0	0	1	0	3.00

Pixie Dust Technologies has a consensus target price of $5.21, indicating a potential upside of 247.33%. Given Pixie Dust Technologies’ higher possible upside, analysts clearly believe Pixie Dust Technologies is more favorable than Endonovo Therapeutics.

Valuation and Earnings

This table compares Endonovo Therapeutics and Pixie Dust Technologies’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Endonovo Therapeutics	$140,000.00	3.12	$6.93 million	N/A	N/A
Pixie Dust Technologies	$5.18 million	4.26	-$14.45 million	N/A	N/A

Endonovo Therapeutics has higher earnings, but lower revenue than Pixie Dust Technologies.

Insider and Institutional Ownership

0.4% of Pixie Dust Technologies shares are owned by institutional investors. 5.6% of Endonovo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Pixie Dust Technologies beats Endonovo Therapeutics on 6 of the 10 factors compared between the two stocks.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

About Pixie Dust Technologies

Pixie Dust Technologies, Inc., a technology company, focuses on personal care and diversity, and workspace and digital transformation businesses primarily in Japan. It offers SonoRepro, an ultrasonic non-contact vibrotactile stimulation scalp care device; VUEVO, a series of directional voice arrival detection devices for individuals with deaf and hard-of-hearing; and kikippa, an acoustic stimulation device functioning as a desk-top speaker. The company also provides iwasemi, a sound-absorbing or sound-proofing material for architectural and interior design firms; hackke, a location positioning technology; KOTOWARI, a technology offering spatial analysis data; and magickiri, a planning services and monitoring service, which monitors human behavior and analyzes the customer's environment on the customer's behalf. In addition, it operates Pixie Nest, a membership forum, which hosts meetings and distributes information to facilitate solving social issues. The company was incorporated in 2017 and is headquartered in Tokyo, Japan.